Abstract
Background: Maintenance therapy with the PARP inhibitor olaparib for metastatic pancreatic cancer (M PC) with a germline BRCA1 or BRCA2 mutation has b......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
